Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

View Full Paper
Ask AI
Bookmark
Share

Authors

AYAndrew J. YeeDCDiana CirsteaPKPrabhjot Kaur

Discussion

Loading...

Member takes

Overview

Multicenter evaluation shows next-generation sequencing improves risk stratification and identifies mutations in myeloma.

Key Points

  • Assess the clinical performance of PlasmaSeq compared to traditional FISH in multiple myeloma diagnosis.
  • Analyzed 155 bone marrow samples from multiple academic institutions using PlasmaSeq and FISH.
  • Used CD138 enrichment for sample preparation prior to next-generation sequencing.
  • Evaluated concordance between PlasmaSeq and FISH results for genomic alterations.
  • PlasmaSeq identified somatic mutations in 59% of clonal multiple myeloma samples.
  • 71% of patients had actionable findings from PlasmaSeq compared to FISH.
  • PlasmaSeq achieved a 100% diagnostic rate in clonal cases, revealing high-risk alterations not detected by FISH.

Cite This Study

Yee et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da84https://doi.org/10.1182/blood-2025-4026
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma2025 · 1 citations
  2. 2Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study2025 · 1 citations
  3. 3Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients2025
  4. 4Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  5. 5Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms2025